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Neuromelanin, neurotransmitter status and
brainstem location determine the differential
vulnerability of catecholaminergic neurons to
mitochondrial DNA deletions
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Abstract
Background: Deletions of the mitochondrial DNA (mtDNA) accumulate to high levels in dopaminergic neurons of
the substantia nigra pars compacta (SNc) in normal aging and in patients with Parkinson’s disease (PD). Human
nigral neurons characteristically contain the pigment neuromelanin (NM), which is believed to alter the cellular
redox-status. The impact of neuronal pigmentation, neurotransmitter status and brainstem location on the
susceptibility to mtDNA damage remains unclear. We quantified mtDNA deletions (ΔmtDNA) in single pigmented
and non-pigmented catecholaminergic, as well as non-catecholaminergic neurons of the human SNc, the ventral
tegmental area (VTA) and the locus coeruleus (LC), using laser capture microdissection and single-cell real-time
PCR.
Results: In healthy aged individuals, ΔmtDNA levels were highest in pigmented catecholaminergic neurons (25.2 ±
14.9%), followed by non-pigmented catecholamergic (18.0 ± 11.2%) and non-catecholaminergic neurons (12.3 ±
12.3%; p < 0.001). Within the catecholaminergic population, ΔmtDNA levels were highest in dopaminergic neurons
of the SNc (33.9 ± 21.6%) followed by dopaminergic neurons of the VTA (21.9 ± 12.3%) and noradrenergic neurons
of the LC (11.1 ± 11.4%; p < 0.001). In PD patients, there was a trend to an elevated mutation load in surviving
non-pigmented nigral neurons (27.13 ± 16.73) compared to age-matched controls (19.15 ± 11.06; p = 0.052), but
levels where similar in pigmented nigral neurons of PD patients (41.62 ± 19.61) and controls (41.80 ± 22.62).
Conclusions: Catecholaminergic brainstem neurons are differentially susceptible to mtDNA damage. Pigmented
dopaminergic neurons of the SNc show the highest ΔmtDNA levels, possibly explaining the exceptional
vulnerability of the nigro-striatal system in PD and aging. Although loss of pigmented noradrenergic LC neurons
also is an early feature of PD pathology, mtDNA levels are not elevated in this nucleus in healthy controls. Thus,
ΔmtDNA are neither an inevitable consequence of catecholamine metabolism nor a universal explanation for the
regional vulnerability seen in PD.
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Background
Oxidative stress and mitochondrial dysfunction are
believed to have a dominant role in mechanisms of aging
and neurodegenerative disorders such as Parkinson disease
(PD) [1]. The mitochondrial theory of aging proposes that
production of reactive oxygen species (ROS) in mitochon-
dria causes accumulating damage to proteins, lipids, and
mitochondrial DNA (mtDNA). As a consequence, mito-
chondrial dysfunction and ROS production may build up
in a vicious cycle that eventually results in cell death [2,3].
Damage to mtDNA is central to this theory and early stu-
dies provide evidence for the accumulation of somatic
mtDNA deletions (ΔmtDNA) in aging postmitotic tissues
with high energy demand, such as skeletal muscle and the
brain [4,5]. Nevertheless, due to the low abundance of
ΔmtDNA detected in crude tissue homogenates, their
functional significance remained controversial. By combin-
ing laser-microdissection (LMD) with a quantitative real-
time PCR (RT-PCR) assay, we demonstrated the age-
related accumulation of clonally expanded ΔmtDNA
in individual post mortem dopaminergic neurons of the
substantia nigra pars compacta (SNc) [6]. Indicative of
a resulting functionally relevant biochemical defect, neu-
rons with high levels (~ 60%) ΔmtDNA had mitochondrial
cytochrome-c oxidase (COX, complex IV of the mitochon-
drial respiratoy chain) deficiency on histochemical exami-
nation in PD patients and controls. These findings were
independently confirmed using a different methodological
approach [7]. Our studies into the regional distribution of
ΔmtDNA further showed that dopaminergic nigral neu-
rons have a higher propensity to accumulate ΔmtDNA
than extranigral populations, e.g. in the putamen, the hip-
pocampus or the frontal cortex [8,9]. Besides their cate-
cholaminergic neurotransmitter status, a prominent
feature of these neurons is their pigmentation, i.e. the
intraneuronal accumulation of neuromelanin (NM). NM
has long been considered a cellular waste product via the
non-enzymatic oxidization of dopamine or other catecho-
lamines, but some evidence points towards a regulated
production that might involve alpha-synuclein [10,11]. Its
contribution to neurodegenerative processes is far from
understood as there is evidence for both neuroprotective
and neurotoxic properties [12-14]. As a possible mechan-
ism, it has been proposed that NM might serve to control
iron homeostasis within pigmented neurons [15]. If the
iron chelation ability of NM is reduced, increased levels of
intra-neuronal free iron may stimulate ROS production. In
PD, pigmented neurons contain less NM than in healthy
brains, while the optical density of the pigment is
increased [16,17]. These changes of neuronal NM content
and composition may cause a loss of protective properties
[18]. Indeed, we have previously shown that individual
dopaminergic neurons have elevated iron levels in PD
[19]. Thus, increased ROS generation, mtDNA mutations
and mitochondrial dysfunction might pave the way for
neurodegenerative processes in PD [20].
In this context the question arises, if location, neuro-
transmitter status or the presence of NM determines the
vulnerability of dopaminergic nigral neurons to accumu-
late mtDNA damage. Herein, we investigated the associa-
tion of these factors with mtDNA levels in single post
mortem catecholaminergic neurons that were dissected
from the SNc, the ventral tegmental area (VTA) and the
locus coeruleus (LC) of post mortem brains of healthy
aged individuals and PD patients.
Results
Association of pigmentation and ΔmtDNA levels
In the adult human brain, NM is easily identifiable as a
black-brown pigment by light microscopy. NM-containing
neurons are distributed throughout the entire brainstem,
but the largest clusters are found in the SNc, the VTA and
the LC [18]. In a pilot experiment, we randomly collected
pigmented neurons from the SNc of five healthy controls
(80.8 ± 8.6 y) and compared ΔmtDNA levels to those seen
in non-pigmented neurons within the same specimens.
We found that non-pigmented neurons had a mean of
31.0 ± 25.1% ΔmtDNA, whereas pigmented neurons had a
mean of 49.2% ± 18.3% ΔmtDNA (p = 0.017). This preli-
minary data suggested that an increased vulnerability is
associated with NM-pigmentation of midbrain neurons in
healthy aged controls.
Encouraged by these results, we next established an
immunohistochemical staining protocol to facilitate a
more specific and extensive analysis of catecholaminergic
neurons of the SNc, the VTA and the LC. Using a succes-
sive TH/NeuN antibody labeling and DAB/HRP reaction,
catecholaminergic (TH+) neurons were positively discrimi-
nated from non-catecholaminergic (TH-) neurons (e.g.
GABAergic interneurons) and from glia cells. TH+ immu-
noreactivity results in a brown cytosolic reaction product,
while TH- neurons remain unstained. NeuN immunoreac-
tivity results in a grey appearance of TH- neurons due to
the successive DAB/Nickel reaction. Pigmented and non-
pigmented neurons were further distinguished by the
visible presence or absence of NM (Figure 1). For these
studies, we extended the analysis with an independent
group of 19 controls (68.8 ± 19.4 y) and 14 PD specimens
(75.1 ± 7.8 y).
We first asked, whether our initial data could be vali-
dated after immunhistochemical identification of cate-
cholaminergic neurons. To this end, we analyzed
ΔmtDNA levels of TH+ neurons captured from all three
regions (SN, VTA and LC). In a combined analysis of
all regions, we confirmed a significant difference of
mtDNA levels between non-pigmented (18.0% ± 11.2%)
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and pigmented neurons (25.2% ± 14.9%; p = 0.003).
Thus, in catecholaminergic brainstem neurons, the pre-
sence of NM is associated with higher ΔmtDNA levels,
independent of location and dopaminergic or noradre-
nergic neurotransmitter status.
Influence of neurotransmitter status on ΔmtDNA levels
We next asked whether ΔmtDNA levels are generally
higher in TH+ (catecholaminergic) compared to TH-
neurons, i.e. neurons that contain neither dopamine nor
noradrenaline. For this analysis, TH-/NeuN+ neurons
were additionally sampled from SN, VTA and LC. RT-
PCR data showed that TH-negative midbrain neurons
had low mtDNA levels of 12.3% ± 12.3. After combining
this and the previous data for statistical analysis, we
found a significant difference between TH- neurons and
pigmented as well as non-pigmented TH+ neurons
(Mann-Whitney-Test; p = 0.005). In these three groups,
Figure 1 Immunohistochemical identification of target neurons. (a+b) Pigmented vs. non-pigmented catecholaminergic neurons. TH+
neurons were identified by their brown cytosolic reaction product. Pigmented (TH+/NM+; top left) and non-pigmented (TH+/NM-; bottom right,
marked for LMD) neurons were further distinguished by the visible presence or absence of NM. (a) TH+/NM- neuron before and (b) after LMD.
(c+d) Catecholaminergic vs. non-catecholaminergic neurons. NeuN+ immunoreactivity results in a grey appearance of TH- neurons due to a
DAB/Nickel reaction (bottom neuron). (c) TH+/NM+ neuron before and (d) after LMD.
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levels of mtDNA increase in the order (Kruskal-Wallis-
Test; p < 0.001): non-catecholaminergic (12.3%) < cate-
cholaminergic/non-pigmented (18.0%) < catecholaminer-
gic/pigmented (25.2%) (Figure 2).
Vulnerability of SNc, VTA and LC neurons
The SNc and VTA both predominately contain dopa-
minergic neurons, while the LC contains noradrenergic
neurons. In the SNc and in the LC the pigment is
found in approximately 95% of neurons, whereas in
the VTA only about 50% neurons are pigmented [11].
We therefore asked, to what extend the location has
an impact on deletion levels independent of neuronal
pigmentation. Combined analysis of pigmented and
non-pigmented TH+ neurons showed an average of
11.1 ± 11.4% ΔmtDNA in the LC, 21.9 ± 12.3% in the
VTA and 33.9 ± 21.6% in the SNc. Interregional differ-
ences were significant between all groups at p < 0.001
(Figure 3). Thus, dopaminergic neurons of the SNc are
more susceptible to ΔmtDNA than those of the VTA
and both are more susceptible than noradrenergic neu-
rons of the LC.
ΔmtDNA levels in PD nigral neurons
Lastly, we quantified ΔmtDNA levels in PD cases (n = 14;
mean age 75.1 ± 7.8 years). Collection and analysis was
restricted to SN dopaminergic neurons due to the paucity
of suitable tissue samples. In PD, ΔmtDNA levels of
pigmented neurons (41.62 ± 19.61) were again higher
than those of non-pigmented neurons (27.13 ± 16.73; p =
9.6E-05), thus independently reproducing the results
seen in the control group. We then compared ΔmtDNA
levels in PD cases to those seen in age-matched controls
(n = 19; mean age 78.7 ± 9.0 years). In non-pigmented
neurons there was a trend to higher deletions in PD vs.
controls (PD = 27.13 ± 16.73; controls = 19.15 ± 11.06;
p = 0.052). No difference was seen for pigmented neu-
rons in PD (41.62 ± 19.61) and controls (41.80 ± 22.62;
Figure 4).
Differential vulnerability of catecholaminergic brainstem
nuclei in healthy aging
To generate a concise picture of ΔmtDNA levels in the
aged human brain, we extracted data coming from all
control individuals over 60 years of age (n = 19; mean
age 78.7 ± 9.0 years). In our synopsis, individual levels of
ΔmtDNA in relation to brainstem location, pigmentation
and neurotransmitter status are illustrated (Figure 5).
This data underlines the prominent vulnerability of pig-
mented nigral neurons, followed by pigmented neurons
of the VTA and non-pigmented neurons of both nuclei,
whereas the LC has overall low deletion levels.
Discussion
Degeneration of pigmented dopaminergic neurons is
one of the neuropathological hallmarks of PD [21,22]. In
these neurons, ROS generation may be enhanced by the
Figure 2 Differential susceptibility of catecholaminergic
pigmented neurons to deletions of mitochondrial DNA. Levels
of ΔmtDNA raise in the order of non-catecholaminergic (TH-/NeuN+)
< catecholaminergic/non-pigmented (TH+/NM-) <
catecholaminergic/pigmented neurons (TH+/NM+). Differences were
significant at p = 0.005 (**; Mann-Whitney-Test) and p = 0.001
(***; Kruskal-Wallis-Test).
Figure 3 Differential vulnerability of SNc, VTA and LC neurons
to deletions of mitochondrial DNA. Lowest levels were seen for
noradrenergic neurons of the LC, followed by dopaminergic
neurons of the VTA and the SNc. Differences were significant at p =
0.001 (***; Kruskal-Wallis-Test).
Elstner et al. Molecular Brain 2011, 4:43
http://www.molecularbrain.com/content/4/1/43
Page 4 of 10
presence of autooxidizable dopamine, low glutathion
and high iron content [23]. Additionally, recent data has
revealed the reliance on Ca2+ channels to maintain
autonomous activity in aging dopaminergic neurons,
causing sustained metabolic stress on mitochondria [24].
Decreased expression of nuclear encoded mitochondrial
genes and of genes in energy-sensing pathways might
further aggravate mitochondrial dysfunction [25]. The
combination of these and other factors likely accelerates
cellular aging processes and propagates clonal expansion
of mtDNA, which are believed to arise during the repair
of oxidatively damaged mtDNA [6,26,27]. COX-deficient
neurons are also found in hippocampal neurons of aged
individuals and Alzheimer’s patients, but dopaminergic
neurons of the SNc accumulate deletions to consider-
ably higher levels [8,9]. These neurons are characterized
by the age-related appearance and accumulation of NM-
pigment. In vitro data provides an intriguing view on
the potential protective and harmful properties of NM,
which might change depending on the melanin species,
its protein component, sulfhydryl residues and the cellu-
lar redox-state. Depletion of glutathione and upregula-
tion of glutathione peroxidase activity in response to
oxidative stress may further drive the production of
neuromelanin [28]. While NM can cause apoptosis of
DA neurons through an impact on mitochondrial redox
state and S-glutathionylation [29], a protective role was
shown in primary mesencephalic neurons under condi-
tions of high oxidative load [30].
Increased ΔmtDNA levels in pigmented neurons
To further elucidate the relationship of pigmentation and
ROS damage in the human brain, we determined
ΔmtDNA levels by RT-PCR analysis of single human post
mortem brainstem neurons that were obtained from con-
trol individuals and PD patients by immunohistochemical
characterization and LMD. The primary finding of this
study is that ΔmtDNA levels are reproducibly elevated in
neurons containing NM compared to non-pigmented neu-
rons. To our knowledge, these data establish for the first
time an association of neuronal pigmentation and mtDNA
damage in human post mortem brain. Due to the limita-
tions of a post mortem study, a causal relationship is diffi-
cult to prove or exclude. On the one hand, NM itself
might cause increased ROS and mtDNA damage leading
to the clonal expansion of ΔmtDNA. On the other hand,
an independent pathophysiological mechanism may
impose cellular stress on these neurons and cause increase
in both, ΔmtDNA levels and NM content.
Only dopaminergic neurons show elevated ΔmtDNA
levels
In the literature, several lines of evidence argue against the
notion that NM is a simple degradation product of cate-
cholamine transmitter metabolism. On the contrary, NM
synthesis and turnover may underlie a yet to determined
enzymatic regulatory process, possibly involving alpha-
synuclein [11,17,31]. While NM is found in most dopami-
nergic neurons of the SN and noradrenergic neurons of
the LC, it does not develop in dopaminergic neurons of
the olfactory bulb, some hypothalamic nuclei, nor in
medullary adrenergic neurons [32]. Moreover, despite the
fact that TH is the rate limiting enzyme in catecholamine
synthesis there is no clear correlation between the degree
of NM pigmentation and TH immunoreactivity [33,34].
We therefore asked, whether ΔmtDNA levels are generally
higher in catecholaminergic than in non-catecholaminer-
gic neurons. We found that in noradrenergic neurons of
the LC, ΔmtDNA were not elevated compared to TH-
neurons. In contrast to this, dopaminergic neurons of the
SNc and VTA have considerably elevated ΔmtDNA levels
(Figure 2) compared to other neuronal populations.
SNc neurons are highly susceptible to ΔmtDNA - LC
neurons are not
During PD disease-progression, intraneuronal pathology
and neurodegeneration are seen in an ‘ascending’ pattern
throughout the entire brain (i.e. Braak stages) [21].
Within the brainstem, catecholaminergic nuclei display a
differential pathology: whereas the LC is affected early in
disease and degeneration is reported to exceed that of
the SNc [35], neuronal survival in the VTA is consider-
ably higher even in severe cases [36,37]. We therefore
sought to determine mtDNA mutation load in these
Figure 4 Levels of mitochondrial DNA deletions in nigral
neurons of PD and controls. Pigmented neurons (TH+/NM+) of the
SNc have considerably higher ΔmtDNA levels than non-pigmented
neurons (TH+/NM-) in controls (C) and PD (*** p = 0.001). In
nonpigmented neurons there was a trend to higher deletions in
PD vs. controls (p = 0.052).
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nuclei in healthy controls. If ΔmtDNA played an integral
part in the selective vulnerability in PD, a regional pat-
tern of ΔmtDNA resembling that of Braak stages might
be seen. Contrary to these expections, we found that
deletion levels were considerably higher in SNc neurons
than in the similarly pigmented LC neurons, (Figure 3).
This raises doubts about a causative continuity of cate-
cholamine metabolism > NMpigmentation > ROS
generation > mtDNA damage. Thus, ΔmtDNA levels are
not tightly associated with the differential neuronal vul-
nerability seen in PD (Figure 5). This finding argues
against the notion that PD pathology is an acceleration of
molecular events found in healthy aging, which has also
been shown in morphometric studies [34]. While the
agedependent loss of DA neurons is a linear process and
mainly affects the dorsal part of the SNc (6,9% loss per
Figure 5 Differential vulnerability of catecholaminergic brainstem neurons in healthy aged controls. 3-D model of the brain showing
location of brainstem nuclei and ΔmtDNA levels of pigmented (TH+/NM+) and non-pigmented (TH+/NM-) catecholaminergic neurons, as well as
non-catecholaminergic (TH-) neurons in these nuclei. Values represent mean ± standard deviation of data collected from healthy aged controls
(78.7 ± 9.0 years). Highest deletion levels are seen in pigmented neurons of the SNc (black). VTA neurons show intermediate ΔmtDNA levels
(grey) and LC neurons lowest (light grey). PD pathology is deviating from this pattern, as SNc and LC show heavy degeneration whereas the
VTA is relatively spared.
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decade), followed by the medial ventral part (5,4% per
decade) and nearly sparing the ventral part (2,1% loss per
decade), neurodegeneration in PD is rapidly progressive
with an overall loss of DA neurons of 45% in the first
decade. Furthermore, the ventral part of the SNc is the
most affected part in this progress with an average loss of
95%, followed by the medial ventral part (71%) and the
dorsal part (56%). It has to be stressed that - due to tissue
limitations - we were not able to analyze the regional dis-
tribution of ΔmtDNA in PD samples to the extent done
for controls. Therefore, we cannot rule out that
ΔmtDNA levels increase to significant levels in the LC or
other neuronal populations affected in PD.
Elevated ΔmtDNA levels in SNc of PD
We further asked, whether ΔmtDNA levels reflect dis-
ease pathology in PD as was suggested by previous stu-
dies [6]. Results from PD cases independently confirmed
higher ΔmtDNA levels in pigmented vs. non-pigmented
neurons. Compared to controls, we found a not signifi-
cant trend to higher ΔmtDNA levels in non-pigmented
SNc neurons of PD brains, but this was not seen for
pigmented neurons (Figure 4). The interpretation of this
data is complicated by the extensive and differential
neuronal loss seen in PD brains. Most severely affected
neurons might have already been lost and probably only
well protected and ‘more resistant’ neurons were left for
sampling. Furthermore, within the SNc, a regional vul-
nerability is seen for PD: nigral neurons of the lightly
pigmented ventral tier degenerate first, while the heavily
pigmented of the dorsal tier are relatively preserved
[16,34,38]. If pigmented neurons are mainly sampled
from the pool of ‘resistant’ neurons located in the dorsal
tier this might result in similar ΔmtDNA levels compar-
ing PD and controls. In this study, the available mid-
brain samples did not allow for the discrimination of
regional differences in PD, but this is planned for future
studies.
Following a different line of argumentation, ΔmtDNA
may simply play no relevant role in the pathogenesis of
PD. Contradicting this notion, high ΔmtDNA levels are
associated with a clear biochemical defect in nigral neu-
rons and the percentage of these COX-deficient neurons
is increased in the SN of PD patients [6]. Furthermore,
gene defects of the mtDNA polymerase g (POLG) result
in the accumulation of ΔmtDNA and can cause parkin-
sonism [39]. Importantly, breakpoint analysis revealed
that the types of ΔmtDNA that have clonally expanded
in nigra neurons from PD patients and age-matched
controls are similar to those from a patient with POLG
mutations who had parkinsonism [40].
This study shows that ΔmtDNA are a common age-
related phenomenon in pigmented nigral neurons, both in
PD patients and healthy individuals. Thus, accumulation
of ΔmtDNA clearly cannot serve as the single explanation
for neurodegeneration in PD, but may precipitate dopa-
mine neuron death in combination with other endogenous
and exogenous factors. Interestingly, recent data implies
that age-related accumulation of NM-pigment might
induce a-synuclein expression, another important factor
determining PD pathology [41].
Conclusions
NM formation and turnover might constitute a protec-
tive system regulating neuronal redox state [11,18]. On
the other hand, NM may contribute to ROS generation
through release of redox-active iron under certain
pathological conditions [15]. In this study, we found
increased ΔmtDNA levels in pigmented midbrain neu-
rons, which is consistent with both theories. Dopami-
nergic neurons have elevated levels of ΔmtDNA,
supporting the role of dopamine metabolism in the gen-
eration of ROS and mtDNA damage. Importantly, in
noradrenergic neurons, a causative relation of pigmenta-
tion, production of ROS and accumulation of ΔmtDNA
cannot be established. Since the LC is affected early and
severely in PD pathology, different factors must account
for the vulnerability of catecholamingergic neurons in
this nucleus.
Methods
Ethics statement
Frozen midbrain tissue was requested from the Newcas-
tle Brain Tissue Resource and the German brain bank
(Brain-Net®). Written consent was obtained with verifi-
cation/assent in writing from next of kin who confirmed
the wishes at time of death. All procedures were in line
with the UK Human Tissue Authority guidance and
approved by the Local Research Ethics Committee. The
study is in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki.
Patients and controls
Control individuals had no prior history of neurological
disease (n = 24, mean age 75.1 ± 7.8 years, post mortem
interval (PMI) 24.0 ± 9.0 hours). Patients had a clinical
and neuropathological diagnosis of PD (n = 14, mean
age 71.3 ± 18.2 years, PMI 32.1 ± 18.7 hours). Neither
age (p = 0.24) nor PMI (p = 0.1) were significantly dif-
ferent between groups. Neuropathological examination
had demonstrated the presence of Lewy body pathology
in the substantia nigra with typical pathological features,
including moderate to severe neuronal loss and gliosis.
Synuclein immunohistochemistry or ubiquitin immuno-
histochemistry was used to confirm findings from H&E
stained sections and cases were graded according to
published criteria for Lewy body disorders (LBD)
[21,42].
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Histology and immunohistochemistry
Unfixed human midbrains stored at -80°C were used for
analysis. 20 μm sections were cut and mounted onto
Leica 2 μm PEN membrane slides (Leica Microsystems,
Wetzlar, Germany) prior to staining and microdissec-
tion. For pilot experiments (n = 5 controls), sections
were stained with cresyl violet (Merck, Darmstadt,
Germany) and dehydrated in an ethanol series. For most
experiments, a successive Tyrosin-Hydroxylase (TH) and
Neuronal Nuclei (NeuN) double-staining was applied. In
detail, frozen sections were fixed in ice-chilled acetone
for 7 minutes and air-dried for 10 minutes at room tem-
perature (RT). All solutions were prepared in phosphate
buffered saline 1% Triton X-100 (PBST) and all incuba-
tions were performed at RT. Sections were washed twice
in PBST and blocked with 5% normal goat serum (NGS)
for 30 min. An anti-mouse poly horseradish peroxidase
(HRP) kit was used for detection of primary antibodies
according to the manufacturers protocol (Millipore,
Billerica, MA, USA). Primary rabbit anti-TH antibody
(abcam, Cambridge, UK) was applied at 1:300 in PBST
with 5% NGS for 60 min and staining was developed
with the DAB Chromogen-Buffer provided with the kit
for 5 min. Sections were washed in tap water followed
by blocking and incubation with 1:400 mouse IgG1 anti-
NeuN (Millipore, Billerica, MA, USA) for 45 min. For
successive NeuN detection, nickel chloride was added to
the DAB substrate solution and developed for 10 min.
The addition of nickel chloride produces a dark grey
appearance of NeuN+ neurons, thereby enabling distinc-
tion from the light brown of DAB-mediated TH+ immu-
nolabelling. Finally, sections were washed, dehydrated in
100% ethanol and air-dried for 30 min. Membrane sec-
tions were used for LMD immediately or frozen at
-20°C for later use.
Quantification of ΔmtDNA
UV-Laser-microdissection was performed on a Leica
LMD6000 microscope (Leica, Wetzlar, Germany). Single
neurons were collected into separate reaction tubes and
DNA was extracted with the DNA Micro Kit (Qiagen,
Düsseldorf, Germany), according to the manufacturer’s
protocol. Quantification of ΔmtDNA levels was based on
the RT-PCR method previously described, using relative
quantification of the mitochondrial ND1 and ND4 genes
by means of the delta-delta-CT-method [6]. Differing
from the original method, we further optimized the RT-
PCR assay to be run as a duplex experiment with quanti-
fication of ND1 and ND4 genes within the same reaction.
Using this protocol, there is high correlation with dele-
tion quantification by southern blot and by the original
method [43]. The following primers (MWG Biotech,
Ebersberg, Germany) and TaqMan probes (Life
Technologies, Carlsbad, CA, USA) were used: ND1 (for-
ward primer nt 3485-3504, reverse primer nt 3553-3532;
VIC-labeled probe nt 3506-3529) and ND4 (forward pri-
mer nt 12087-12109, reverse primer nt 12170-12140,
FAM-labeled probe nt 12111-12138). Final concentra-
tions were 900nM for primers and 250nM for probes.
The Taqman Universal PCR Mastermix (Life Technolo-
gies, Carlsbad, CA, USA) was used for the assay in a 25
μl reaction mix per sample. Experiments were performed
on an Applied Biosystems StepOnePlusTM system (Life
Technologies, Carlsbad, CA, USA). Standard cycling con-
ditions were used as follows: activation for 2 minutes @
50°C followed by 10 minutes @ 95°C; PCR (40 cycles) for
15 seconds @ 95°C followed by 1 minute at 60°C. Sam-
ples were analyzed in triplicates and the resulting mean
values were used for statistical analysis.
Statistical analysis and graphic design
All statistical analyses were performed with SPSS 18.0 for
Mac (PASW Statistics, IBM). A total of 383 neurons were
captured and mtDNA deletion levels were analyzed for
every single neuron. Data of all neurons was available for
analysis. Since the mtDNA deletion values did not have a
normal distribution (Kolmogorov-Smirnov-Test p =
0.007), we performed non-parametric tests for all statisti-
cal procedures (Mann-Whitney-Test and Kruskal-Wallis
one-way analysis of variance). Values are expressed as
mean ± standard deviation. Box plots show median, lower
and upper quartile. Whiskers are extended to extreme
data points. Figure 5 was generated using Cinema 4D
(Maxon, Friedrichsdorf, Germany).
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